- Home
- HYFM vs BOLT Comparison
HYFM vs BOLT Comparison
Compare HYFM & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYFM | BOLT |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 10.5M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HYFM | BOLT |
|---|---|---|
| Price | $1.19 | $4.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 35.2K | 19.7K |
| Earning Date | 01-01-0001 | 06-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $190,288,000.00 | $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $51.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.86 | $0.26 |
| 52 Week High | $4.78 | $7.35 |
Technical Indicators
Market Signals| Indicator | HYFM | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 32.11 |
| Support Level | $0.86 | $0.27 |
| Resistance Level | $1.55 | $5.45 |
| Average True Range (ATR) | 0.14 | 0.33 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 55.56 | 0.00 |
Price Performance
Historical ComparisonAbout HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.